FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 720 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Olanzapine Reduces Nausea and Vomiting Caused by Advanced Cancer June 12, 2020 Beating the Heat with Beets July 31, 2020 HPV Vaccine May Provide Men with “Herd Immunity” against Oral HPV... October 8, 2019 Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer August 28, 2019 Load more HOT NEWS Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has... Woman with Breast Cancer May Have Saved Her Twin’s Life by... Encouraging Early Results Seen with Novel MEDI1191 in Advanced Tumours First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years...
